Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Getting $529 Per Course For Paxlovid Under US Contract; Did Merck Drive A Harder Bargain?

Executive Summary

US government is paying Merck & Co. around $181 more per course of treatment for its oral antiviral for COVID-19, molnupiravir, than it is to Pfizer for its competing drug.

You may also be interested in...



Merck Molnupiravir Advisory Committee To Consider Pregnancy Risk, Viral Mutations

US FDA seems poised to authorize the oral COVID treatment, but panel discussion will likely highlight the limitations of the antiviral.

Could This Be Pfizer’s Biggest Week At The US FDA For COVID Products?

With an EUA submission for its Paxlovid treatment pill and expected authorization for universal adult vaccine boosters, Pfizer is establishing a portfolio of COVID products that could be used well after the eventual lifting of the public health emergency.

Pfizer & MPP Sign Deal For Generics Of COVID-19 Candidate Paxlovid

An agreement allowing the production and distribution of the US firm’s new protease inhibitor in 95 countries has been welcomed by the Medicines Patent Pool. But some medicines access advocates are not so sure it’s necessarily a good deal for lower-income countries.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS145287

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel